Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01862081
Title A Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer
Recruitment Completed
Gender female
Phase Phase I
Variant Requirements No
Sponsors Genentech, Inc.
Indications

breast adenocarcinoma

Therapies

Docetaxel + Taselisib

Paclitaxel + Taselisib

Age Groups: adult
Covered Countries USA | ESP | CAN | BEL


No variant requirements are available.